Avalon Pharmaceuticals to Present at 20th Annual Roth Capital Partners Growth Stock Conference
February 14 2008 - 7:00AM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that C.
Eric Winzer, Executive Vice President and CFO, will provide an
update on the Company at the 20th Annual Roth Capital Partners
Growth Stock Conference. The conference will be held at The Ritz
Carlton in Laguna Niguel, CA, February 18-21. Mr. Winzer is
scheduled to present on Tuesday, February 19, at 11:00am. About
Avalon Pharmaceuticals Avalon is a biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class cancer therapeutics. Avalon�s lead product
candidate, AVN944,�an IMPDH inhibitor, is in Phase II clinical
development. Avalon also has preclinical programs to develop
inhibitors of the Beta-catenin and Aurora/Centrosome
pathways,�discovery programs�for�inhibitors of�the Survivin�and
Myc�pathways and partnerships with Merck, MedImmune, ChemDiv,
Medarex, and Novartis. AvalonRx� is the company�s proprietary
platform�which is based on�large-scale�biomarker identification and
monitoring, used to discover and develop therapeutics for pathways
that have historically been characterized as "undruggable." Avalon
is headquartered in Germantown, MD. Safe Harbor Statement This
announcement contains, in addition to historical information,
certain forward-looking statements that involve risks and
uncertainties. Such statements reflect the current views of Avalon
management and are based on certain assumptions. Actual results
could differ materially from those currently anticipated as a
result of a number of factors, risks and uncertainties, including
those specified under the �Risk Factors� section of our 2006 Annual
Report on Form 10-K and updates contained in subsequent filings we
make with the Securities and Exchange Commission.
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Avalon Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Avalon Pharmaceuticals, Inc. News Articles